BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:iii42-50. [PMID: 27573756 DOI: 10.1093/annonc/mdw305] [Cited by in Crossref: 72] [Cited by in F6Publishing: 86] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Parejo-Alonso B, Royo-García A, Espiau-Romera P, Courtois S, Curiel-García Á, Zagorac S, Villaoslada I, Olive KP, Heeschen C, Sancho P. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Biomed Pharmacother 2023;158:114162. [PMID: 36571997 DOI: 10.1016/j.biopha.2022.114162] [Reference Citation Analysis]
2 Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. Cancers (Basel) 2022;14. [PMID: 36551587 DOI: 10.3390/cancers14246101] [Reference Citation Analysis]
3 Jiang Y, Shi Y, Liu Y, Wang Z, Ma Y, Shi X, Lu L, Wang Z, Li H, Zhang Y, Liu C, Zhang S, Zhong Z, Lu J, Shi M, Shen B, Zhou G, Yin R, Galetta D, Grenda A, Romero A, Hughes BGM, Chen C, Wang X, Feng J. Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Transl Lung Cancer Res 2022;11:2521-38. [PMID: 36636415 DOI: 10.21037/tlcr-22-857] [Reference Citation Analysis]
4 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
5 Liu Z, Li X, Gao J, Yin P, Teng Y, Yu P. The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. Biochemical Pharmacology 2022;205:115294. [DOI: 10.1016/j.bcp.2022.115294] [Reference Citation Analysis]
6 Barbar J, Armach M, Hodroj MH, Assi S, El Nakib C, Chamseddine N, Assi HI. Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Medicine 2022;10:205031212211323. [DOI: 10.1177/20503121221132352] [Reference Citation Analysis]
7 Parejo-alonso B, Royo-garcía A, Espiau-romera P, Courtois S, Curiel-garcía Á, Zagorac S, Villaoslada I, Olive KP, Heeschen C, Sancho P. ALK signaling drives tumorigenicity and chemoresistance of pancreatic ductal adenocarcinoma cells.. [DOI: 10.1101/2022.08.29.505637] [Reference Citation Analysis]
8 Papageorgiou S, Pashley SL, O'Regan L, Khan S, Bayliss R, Fry AM. Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers (Basel) 2022;14:3452. [PMID: 35884511 DOI: 10.3390/cancers14143452] [Reference Citation Analysis]
9 Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Nahit Şendur MA. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol 2022. [PMID: 35734870 DOI: 10.2217/fon-2022-0083] [Reference Citation Analysis]
10 Giunta EF, Signori A, West HJ, Metro G, Friedlaender A, Parikh K, Banna GL, Addeo A. Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Front Oncol 2022;12:921854. [DOI: 10.3389/fonc.2022.921854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 He L, Dar AC. Targeting drug-resistant mutations in ALK. Nat Cancer 2022;3:659-61. [PMID: 35726064 DOI: 10.1038/s43018-022-00390-1] [Reference Citation Analysis]
12 Maraqa B, Al-Ashhab M, Sughayer MA. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan. J Int Med Res 2022;50:3000605221104181. [PMID: 35689392 DOI: 10.1177/03000605221104181] [Reference Citation Analysis]
13 Yu Y, Zhu F, Zhang W, Lu S. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. J Clin Med 2022;11:2963. [PMID: 35683354 DOI: 10.3390/jcm11112963] [Reference Citation Analysis]
14 Seo HY, Kim SC, Roh WL, Shin YK, Kim S, Kim DW, Kim TM, Ku JL. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types. Sci Rep 2022;12:6345. [PMID: 35428753 DOI: 10.1038/s41598-022-10318-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang L, Feng X, Jiao Z, Gan J, Meng Q. Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wolf J, Helland Å, Oh IJ, Migliorino MR, Dziadziuszko R, Wrona A, de Castro J, Mazieres J, Griesinger F, Chlistalla M, Cardona A, Ruf T, Trunzer K, Smoljanovic V, Novello S. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open 2022;7:100333. [PMID: 35042152 DOI: 10.1016/j.esmoop.2021.100333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Therizols G, Bash-Imam Z, Panthu B, Machon C, Vincent A, Ripoll J, Nait-Slimane S, Chalabi-Dchar M, Gaucherot A, Garcia M, Laforêts F, Marcel V, Boubaker-Vitre J, Monet MA, Bouclier C, Vanbelle C, Souahlia G, Berthel E, Albaret MA, Mertani HC, Prudhomme M, Bertrand M, David A, Saurin JC, Bouvet P, Rivals E, Ohlmann T, Guitton J, Dalla Venezia N, Pannequin J, Catez F, Diaz JJ. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nat Commun 2022;13:173. [PMID: 35013311 DOI: 10.1038/s41467-021-27847-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jalal SI, Mamdani H, Turchi AM, Turchi JJ. Lung Cancer. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00063-3] [Reference Citation Analysis]
19 Botticelli A, Pomati G, Marchetti P. Target therapy in cancer treatment. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00152-6] [Reference Citation Analysis]
20 Li W, Zhang J, Wang Z, Li L, Ma J, Zhou X, Wang J, Liang Z, Ying J. Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. Journal of the National Cancer Center 2021;1:123-31. [DOI: 10.1016/j.jncc.2021.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang M, Wang Q, Ke Z, Liu Y, Guo H, Fang S, Lu K. LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis. Front Pharmacol 2021;12:759267. [PMID: 34630126 DOI: 10.3389/fphar.2021.759267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Tanaka M, Siemann DW. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer. Int J Mol Sci 2021;22. [PMID: 34576116 DOI: 10.3390/ijms22189953] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Pan T, Dan Y, Guo D, Jiang J, Ran D, Zhang L, Tian B, Yuan J, Yu Y, Gan Z. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem 2021;224:113672. [PMID: 34237620 DOI: 10.1016/j.ejmech.2021.113672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
24 Gupta R, Smalley M, Anusim N, Jindal V, Singh Rahi M, Gupta S, Gupta S, Jaiyesimi I. Paradigm shift in the management of metastatic nonsmall cell lung cancer. Int J Clin Pract 2021;:e14533. [PMID: 34129744 DOI: 10.1111/ijcp.14533] [Reference Citation Analysis]
25 Pan Y, Xiao W, Ye F, Wang H, Shen Y, Yu X, Han X, Chu Q, Zhou C, Zhang Z, Ren S. Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. Ann Transl Med 2021;9:1014. [PMID: 34277814 DOI: 10.21037/atm-21-2769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 2021;14:3037-49. [PMID: 33994796 DOI: 10.2147/OTT.S291801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Draganov D, Vazvaei F, Donzelli M, Paehler A, Merchant M, Yu L. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol 2020;22:819-29. [PMID: 32383735 DOI: 10.1093/neuonc/noaa052] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
28 Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021;39:1253-63. [PMID: 33646820 DOI: 10.1200/JCO.20.03025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
29 Hofman P. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice. Cells 2021;10:168. [PMID: 33467720 DOI: 10.3390/cells10010168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
30 Ming L, Sun T, Ding H, He J, Wu W, Zhang M, Yang S, Xu H, Ni F, Pan S, Zhang Q, Lin Y. Lung Disease. Clinical Molecular Diagnostics 2021. [DOI: 10.1007/978-981-16-1037-0_38] [Reference Citation Analysis]
31 Harrer DC, Menhart K, Mayer S, Herr W, Reichle A, Vogelhuber M. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report. Front Oncol 2020;10:585830. [PMID: 33134180 DOI: 10.3389/fonc.2020.585830] [Reference Citation Analysis]
32 Murciano-Goroff YR, Taylor BS, Hyman DM, Schram AM. Toward a More Precise Future for Oncology. Cancer Cell 2020;37:431-42. [PMID: 32289268 DOI: 10.1016/j.ccell.2020.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
33 Zhang C, Wang Z, Zhuang R, Guo X, Feng Y, Shen F, Liu W, Zhang Y, Tong H, Sun W, Liu J, Wang G, Dai C, Lu W, Zhou Y. Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing. Onco Targets Ther 2020;13:10335-42. [PMID: 33116613 DOI: 10.2147/OTT.S270481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Reinhart S, Trachsel Y, Fritz C, Wagner U, Bode-Lesniewska B, John H, Pless M. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition. Urology 2020;146:32-5. [PMID: 33007314 DOI: 10.1016/j.urology.2020.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Upadhya A, Yadav KS, Misra A. Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opin Drug Deliv 2021;18:73-102. [PMID: 32954834 DOI: 10.1080/17425247.2021.1825377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Urbán L, Dóczi R, Vodicska B, Kormos D, Tóth L, Takács I, Várkondi E, Tihanyi D, Lakatos D, Dirner A, Vályi-Nagy I, Peták I. Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. J Pers Med 2020;10:E107. [PMID: 32872120 DOI: 10.3390/jpm10030107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Singh A, Chen H. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors. Cancer Manag Res 2020;12:6615-28. [PMID: 32821158 DOI: 10.2147/CMAR.S260274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
38 Jahanzeb M, Lin HM, Pan X, Yin Y, Wu Y, Nordstrom B, Socinski MA. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer. Oncologist 2020;25:867-77. [PMID: 32490560 DOI: 10.1634/theoncologist.2020-0011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
39 Ding N, You A, Tian W, Gu L, Deng D. Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci 2020;16:2595-611. [PMID: 32792859 DOI: 10.7150/ijbs.45886] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
40 Lin HM, Pan X, Hou P, Huang H, Wu Y, Ren K, Jahanzeb M. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. J Med Econ 2020;23:894-901. [PMID: 32347754 DOI: 10.1080/13696998.2020.1762620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hoang T, Myung SK, Pham TT, Kim J, Ju W. Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials. J Clin Med 2020;9:E1063. [PMID: 32283699 DOI: 10.3390/jcm9041063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ding N, You A, Tian W, Gu L, Deng D. Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation.. [DOI: 10.1101/2020.03.28.012971] [Reference Citation Analysis]
43 Wang M, Wang G, Ma H, Shan B. Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety. Curr Cancer Drug Targets 2019;19:41-9. [PMID: 28669346 DOI: 10.2174/1568009617666170623115846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Hoang T, Myung SK, Pham TT, Park B. Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials. Cancers (Basel). 2020;12. [PMID: 32106398 DOI: 10.3390/cancers12030526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
45 Zhu C, Zhuang W, Chen L, Yang W, Ou WB. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 2020;9:111-38. [PMID: 32206559 DOI: 10.21037/tlcr.2020.01.09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
46 Pinto JA, Raez LE, Domingo G. Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Rev Respir Med 2020;14:385-90. [PMID: 31971859 DOI: 10.1080/17476348.2020.1721285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nat Commun 2019;10:5428. [PMID: 31780656 DOI: 10.1038/s41467-019-13315-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
48 Tiotiu A, Billon Y, Vaillant P, Menard O, Hofman P, Mascaux C. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer]. Rev Mal Respir 2019;36:1107-16. [PMID: 31727555 DOI: 10.1016/j.rmr.2019.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Yu H, Sun S, Hu X, Xia J, Wang J, Chen H. Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. Onco Targets Ther 2019;12:6481-95. [PMID: 31616158 DOI: 10.2147/OTT.S185115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Radaram B, Pisaneschi F, Rao Y, Yang P, Piwnica-Worms D, Alauddin MM. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib. Eur J Med Chem 2019;182:111571. [PMID: 31425908 DOI: 10.1016/j.ejmech.2019.111571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
51 Kawata AK, Lenderking WR, Eseyin OR, Kerstein D, Huang J, Huang H, Zhang P, Lin HM. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. J Med Econ 2019;22:924-35. [PMID: 31125274 DOI: 10.1080/13696998.2019.1624080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. Br J Cancer 2019;121:131-8. [PMID: 31217479 DOI: 10.1038/s41416-019-0503-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
53 Paik J, Dhillon S. Alectinib: A Review in Advanced, ALK-Positive NSCLC. Drugs. 2018;78:1247-1257. [PMID: 30030733 DOI: 10.1007/s40265-018-0952-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
54 Umbela S, Ghacha S, Matuknauth R, Gause S, Joshee S, Deshmukh RR. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer. Curr Probl Cancer 2019;43:100477. [PMID: 31109722 DOI: 10.1016/j.currproblcancer.2019.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Guan H, Sheng Y, Guo W, Han S, Shi L. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Adv Ther 2019;36:1114-25. [PMID: 30900201 DOI: 10.1007/s12325-019-00908-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
56 Maury JM, Merveilleux du Vignaux C, Drevet G, Zarza V, Chalabreysse L, Maisse C, Gineys B, Dolmazon C, Tronc F, Girard N, Leroux C. Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas. PLoS One 2019;14:e0197655. [PMID: 30897085 DOI: 10.1371/journal.pone.0197655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
57 Ni J, Li G, Yang X, Chu L, Wang J, Li Y, Zou L, Li Y, Xie C, Zhu Z. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses. Radiat Oncol 2019;14:44. [PMID: 30866974 DOI: 10.1186/s13014-019-1240-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
58 Patel M, Malhotra J, Jabbour SK. Examining EML4-ALK variants in the clinical setting: the next frontier? J Thorac Dis 2018;10:S4104-7. [PMID: 30631567 DOI: 10.21037/jtd.2018.11.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Chang X, Liu Z, Man S, Roys A, Li Z, Zuo D, Wu Y. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. RSC Adv 2019;9:17921-17932. [DOI: 10.1039/c9ra02258a] [Reference Citation Analysis]
60 Li J, Huang Y, Wu M, Wu C, Li X, Bao J. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. Sci Rep 2018;8:10664. [PMID: 30006516 DOI: 10.1038/s41598-018-28752-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
61 Patel M, Jabbour SK, Malhotra J. ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water? J Thorac Dis 2018;10:S2198-201. [PMID: 30123560 DOI: 10.21037/jtd.2018.06.118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
62 Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol 2018;25:S59-67. [PMID: 29910648 DOI: 10.3747/co.25.3760] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
63 Maury J, du Vignaux CM, Drevet G, Zarza V, Chalabreysse L, Tronc F, Girard N, Leroux C. Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas.. [DOI: 10.1101/317297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac Dis 2018;10:S1482-93. [PMID: 29951300 DOI: 10.21037/jtd.2018.05.106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
65 Brastianos PK, Ippen FM, Hafeez U, Gan HK. Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. Oncologist 2018;23:1063-75. [PMID: 29703764 DOI: 10.1634/theoncologist.2017-0614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
66 Facchinetti F, Friboulet L. Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. Transl Lung Cancer Res 2018;7:S103-6. [PMID: 29782561 DOI: 10.21037/tlcr.2018.02.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
67 Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: current status and perspectives. Current Opinion in Oncology 2018;30:69-76. [DOI: 10.1097/cco.0000000000000429] [Cited by in Crossref: 55] [Cited by in F6Publishing: 66] [Article Influence: 11.0] [Reference Citation Analysis]
68 De Carlo E, Del Savio MC, Polesel J, Da Ros V, Berto E, Santarossa S, Chimienti E, Fratino L, Bearz A. Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. Oncotarget 2018;9:15340-9. [PMID: 29632648 DOI: 10.18632/oncotarget.24573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Yang L, Che Y, Guo L, Zheng B, Wang B, Yang Z, Zhu Y, Li J. Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China. Thorac Cancer 2018;9:439-44. [PMID: 29400000 DOI: 10.1111/1759-7714.12595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K. Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers. Cancers (Basel) 2018;10:E10. [PMID: 29300322 DOI: 10.3390/cancers10010010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
71 Yoneda K, Tanaka F. Molecular Diagnosis and Targeting for Lung Cancer. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy 2018. [DOI: 10.1007/978-981-10-6469-2_1] [Reference Citation Analysis]
72 De Pas T, Pala L, Catania C, Conforti F. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. Future Oncology 2017;13:2629-44. [DOI: 10.2217/fon-2017-0262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
73 Manicone M, Scaini MC, Rodriquenz MG, Facchinetti A, Tartarone A, Aieta M, Zamarchi R, Rossi E. Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. J Thorac Dis 2017;9:S1391-6. [PMID: 29184678 DOI: 10.21037/jtd.2017.08.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
74 Mayekar MK, Bivona TG. Current Landscape of Targeted Therapy in Lung Cancer. Clin Pharmacol Ther 2017;102:757-64. [PMID: 28786099 DOI: 10.1002/cpt.810] [Cited by in Crossref: 103] [Cited by in F6Publishing: 111] [Article Influence: 17.2] [Reference Citation Analysis]
75 Tsongalis GJ, Coleman WB. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice. J Clin Pharmacol 2017;57 Suppl 10:S60-6. [PMID: 28921651 DOI: 10.1002/jcph.934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
76 Hofman P. ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients. Cancers (Basel) 2017;9:E106. [PMID: 28805673 DOI: 10.3390/cancers9080106] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
77 Hofman P. ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers (Basel) 2017;9:E107. [PMID: 28805682 DOI: 10.3390/cancers9080107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
78 Pailler E, Faugeroux V, Oulhen M, Catelain C, Farace F. Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time? Transl Lung Cancer Res 2017;6:444-53. [PMID: 28904888 DOI: 10.21037/tlcr.2017.07.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
79 Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther 2017;11:2047-63. [PMID: 28740365 DOI: 10.2147/DDDT.S113500] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
80 Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res 2017;77:2222-30. [PMID: 28461563 DOI: 10.1158/0008-5472.CAN-16-3072] [Cited by in Crossref: 44] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
81 Facchinetti F, Rossi G, Bria E, Soria J, Besse B, Minari R, Friboulet L, Tiseo M. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treatment Reviews 2017;55:83-95. [DOI: 10.1016/j.ctrv.2017.02.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
82 Murray HC, Dun MD, Verrills NM. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. Expert Opin Drug Discov 2017;12:431-47. [PMID: 28286965 DOI: 10.1080/17460441.2017.1304377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
83 Huang JL, Zeng J, Wang F, Huang QT, Lu JB, Li XM, Chen WQ, Zhu CM, Jin JT, Lin SX. Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions. Per Med 2017;14:99-107. [PMID: 29754556 DOI: 10.2217/pme-2016-0080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
84 Roskoski R. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacological Research 2017;117:343-56. [DOI: 10.1016/j.phrs.2017.01.007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 12.0] [Reference Citation Analysis]
85 Solomon B, Soria J. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options – an overview. Annals of Oncology 2016;27:iii1-3. [DOI: 10.1093/annonc/mdw300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]